Authors
Latest:
Reducing site burden and expanding research capacity with AIHow artificial intelligence could enhance clinical trials.
Latest:
Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMODr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Latest:
How I use MicroPulse Laser to treat DMEDr. Jorge Calzada shares his methods for treating diabetic macular edema with MicroPulse Laser and anti-VEGF injections.
Latest:
Key Takeaways on Managing Neovascular AMD and DMENathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.
Latest:
Training and practice are key to learning retinal injection techniquesIn-person and virtual trainings, coupled with the support of local product representatives, are the best ways to ensure retina specialists are set up for success.
Latest:
Managing retinal folds, role of anterior vitreous in retinal detachmentsGrazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.
Latest:
Comparing vorolanib intravitreal insert with aflibercept in DME treatmentEYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.
Latest:
Transforming preinjection protocolsThe role of compounded anesthetic formulations in streamlining efficiency and elevating patient care.
Latest:
Snowmass Retina & Eye 2025: Ronald Frenkel, MD, previews the unique agenda with a fusion of retina, cataract, and glaucomaThe 15th annual meeting, taking from March 24–28 in Snowmass, Colorado, will deliver high-impact discussions on macular disease, artificial intelligence in ophthalmology, and breakthrough therapies—plus opportunities for networking on and off the slopes.
Latest:
Early intervention helps with vision protection in macular degenerationRetina specialist Priya Vakharia, MD, reveals promising ANX007 trial results, showing potential to prevent vision loss in geographic atrophy.
Latest:
What is encapsulated cell therapy?John Pollack, MD, discusses gene therapy advancements in the first installment of his blog for Modern Retina.
Latest:
True-to-life retinal imaging with the new ultra-widefield color RGB modalityDigital exclusive article on red-blue-green ultrawidefield (UWF) imaging
Latest:
Health Canada approves aflibercept biosimilar AflivuHealth Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
Latest:
Two Faricimab Patient Cases from the Real-world in Neovascular AMDDr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.
Latest:
A field guide to optic disc drusenClinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.
Latest:
Making the case for nurses to inject dexamethasone implantsSafety data on non-clinician-led services have shown a low complication rate
Latest:
The significance of imaging and treatment in lattice retinal degenerationPrompt evaluation and adherence to guidelines for treatment recommendations for lattice retinal degeneration are essential to the preservation of vision and sight.
Latest:
Gene therapy: Where the action is for retinal diseasesFoundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.
Latest:
New dawn of GA management requires renewed attention to imagingIt is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).
Latest:
Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trials in nAMDDr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).
Latest:
Ultra-widefield imaging can enhance efficiency for practicesPhysicians can discover, diagnose, document, treat diseases that might go undetected
Latest:
Noninfectious uveitis: Meeting the challengeChronic cases can be difficult for retina specialists; treatment is satisfying.
Latest:
Achieving high-definition slit lamp imaging via smartphone mirroringThis affordable device allows the view through a slit lamp to be shared in real time or recorded, for teaching and reference purposes.
Latest:
Satellite clinics and other strategies to enhance rural ophthalmologyProactive communication and leveraging advanced, yet reliable, technologies to maximize efficiency are essential pillars of success.
Latest:
The future of retina careRetina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting.
Latest:
Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disordersThe use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
